Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis

Moazzam Shahzad, Aleenah Mohsin, Muhammad Kashif Amin, Aqeeb Ur Rehman, Sibgha Gull Chaudhary, Iqra Anwar, Matthew McGuirk, Mohammad Ammad Ud Din, Leyla O. Shune, Al-Ola Abdallah, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2024-199442

Published: 2024

Journal Articles

Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes

Muhammad Umair Mushtaq, Amir Kasaeian, Sibgha Gull Chaudhary, Muhammad Kashif Amin, Naghmeh Khavandgar, Hediyeh Alemi, Muhammad Fareed Khalid, Iqra Anwar, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2024-201164

Published: 2024

Journal Articles

Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Muhammad Umair Mushtaq, Amir Kasaeian, Muhammad Kashif Amin, Hediyeh Alemi, Naghmeh Khavandgar, Aqeeb Ur Rehman, Sibgha Gull Chaudhary, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2024-199559

Published: 2024

Journal Articles

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Blood (2024) 144 (Supplement 1): 5170.5.

https://doi.org/10.1182/blood-2024-211053

Published: 2024

Journal Articles

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 5170.4.

https://doi.org/10.1182/blood-2024-211018

Published: 2024

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis

Muhammad Umair Mushtaq, Amir Kasaeian, Sibgha Gull Chaudhary, Muhammad Kashif Amin, Hediyeh Alemi, Naghmeh Khavandgar, Iqra Anwar, Sohaib Irfan, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2024-200031

Published: 2024

Journal Articles

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Blood (2024) 144 (Supplement 1): 497.

https://doi.org/10.1182/blood-2024-198669

Published: 2024

Journal Articles

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Fathima Shehnaz Ayoobkhan, Raabia Qureshi, Raeef L Rahman, Zohaa Faiz, Sohaib Irfan, Ahmad Iftikhar, Briha Ansari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Shahzad Raza, Hira Shaikh, Forat Lutfi, Shebli Atrash, Joseph P. McGuirk, Hamza Hashmi, Faiz Anwer, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2024-208307

Published: 2024

Journal Articles

Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma

Michael Weise, Shebli Atrash, Briha Ansari, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2024-207882

Published: 2024

Journal Articles

Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis

Priyanka Venkatesh, Razan Mansour, Hamid Ehsan, Nausheen Ahmed, Muhammad Umair Mushtaq, Al-Ola Abdallah, Shebli Atrash, Barry Paul

Blood (2024) 144 (Supplement 1): 3317.

https://doi.org/10.1182/blood-2024-207270

Published: 2024

Journal Articles

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Rachel Dileo, Prerna Mewawalla, Gina Patrus, Christopher Strouse, Ethan Chen, Hira Shaikh, James A Davis, Kimberly M Green, Omar Alkharabsheh, Aliya Rashid, Bidushi Pokhrel, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2024-206059

Published: 2024

Journal Articles

Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma

Fathima Shehnaz Ayoobkhan, Sara Shatnawi, Moazzam Shahzad, Aqeeb Ur Rehman, Sohaib Irfan, Raabia Qureshi, Arooq Khalid, Sibgha Gull Chaudhary, Faiz Anwer, Briha Ansari, Joseph P. McGuirk, Mohamad Mohty, Nausheen Ahmed, Al-Ola Abdallah, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 5045.

https://doi.org/10.1182/blood-2024-203904

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Jordan Snyder, Chelsea Gorsline, Dilek Ince, Aneela Majeed, Faiz Anwer, Hira Shaikh, Abdullah Mohammad Khan, Al-Ola Abdallah, Kimberly M Green, Shebli Atrash, Claire Yun Kyoung Ryu Tiger, Prerna Mewawalla, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2024-208349

Published: 2024

Journal Articles

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Hannah Katz, Lauren N Scott, Pilar Thangwaritorn, Jianzheng Wu, William Wesson, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi, Sunil Abhyankar, Leyla O. Shune, Muhammad Umair Mushtaq, Anurag Singh, Haitham Abdelhakim, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Liz Muenks, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5030.

https://doi.org/10.1182/blood-2024-199312

Published: 2024

Journal Articles

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Ishita Kamboj, Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, James A Davis, Aliya Rashid, Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Abdullah Mohammad Khan, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 2411.2.

https://doi.org/10.1182/blood-2024-199187

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Abdullah Mohammad Khan, Al-Ola Abdallah, Nausheen Ahmed, Shebli Atrash, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2024-208692

Published: 2024

Journal Articles

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Lauren N Scott, William Wesson, Pilar Thangwaritorn, Raeef L Rahman, Forat Lutfi, Marc Hoffmann, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 389.

https://doi.org/10.1182/blood-2024-205983

Published: 2024

Journal Articles

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Jordan Snyder, Dennis Grauer, Nausheen Ahmed, Al-Ola Abdallah, Marc Hoffmann, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 935.

https://doi.org/10.1182/blood-2024-199893

Published: 2024

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Journal Articles

The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Barry Skikne, Tara L. Lin, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Omar Alkharabsheh, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2024-205757

Published: 2024

NARROW

Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis

Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes

Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma

Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only